Abstract
Therapeutic blocking antibodies against programmed death 1 (PD1) and cytotoxic T-lymphocyte antigen 4 (CTLA4) are applied for advanced cancer therapy, but induce a wide range of immune-related adverse events. In our recent case of a 52-year-old female doctor suffering from breast cancer having metastasized to the lung and liver, it was decided to use nivolumab to prevent the disease progressing after excisional surgeries and multiple chemotherapies. One month after completing the nivolumab course, fatigue, hypoglycemia and hypotension developed and isolated ACTH deficiency (IAD) was diagnosed. A further month later, under steroid supplementation, hyperglycemia emerged alongside thirst and polydipsia, prompting a diagnosis of fulminant type 1 diabetes (FT1D). Her susceptibility to type 1 diabetes was examined by HLA haplotype and CTLA4 gene polymorphism analyses. Polymorphisms CT60G>A and +49G>A in CTLA4 both generated a GG genotype. Our patient manifested one of the rarest combinations of autoimmune disease induced by nivolumab. Whereas the HLA haplotype was unsusceptible to autoimmune type 1 diabetes, polymorphisms of CTLA4, the antibody of which frequently causes hypophysitis, were susceptible to FT1D. Peripheral modulation o...Continue Reading
References
Jul 9, 2003·The Journal of Experimental Medicine·Mohammed Javeed I AnsariMohamed H Sayegh
Dec 23, 2004·The Journal of Clinical Endocrinology and Metabolism·Sophie Vallette-KasicJacques Drouin
Jan 7, 2005·Endocrine Reviews·Patrizio CaturegliNoel R Rose
Jan 20, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·N KaravitakiD Wade
Nov 2, 2006·Pituitary·Massimiliano AndrioliFrancesco Cavagnini
Apr 30, 2008·Diabetes Care·Eiji KawasakiKatsumi Eguchi
Jan 6, 2009·Hormones : International Journal of Endocrinology and Metabolism·Vassiliki SyriouMargarita Anapliotou
Jan 17, 2009·Diabetes Research and Clinical Practice·Scherezade MominFrancisco Perez-Bravo
Nov 16, 2010·Seminars in Oncology·Margaret K CallahanJames P Allison
Feb 18, 2014·Journal of Leukocyte Biology·Luis C Antón, Jonathan W Yewdell
Aug 1, 2014·The Journal of Clinical Endocrinology and Metabolism·Alexander T FajeLisa Nachtigall
Jul 19, 2015·Pituitary·Alexander Faje
Oct 16, 2015·Internal Medicine·Nobumasa OharaHideo Sasaki
Apr 21, 2016·Trends in Endocrinology and Metabolism : TEM·Maria J L KrachtBart O Roep
Jun 17, 2016·The Oncologist·Elisa González-RodríguezUNKNOWN Spanish Group for Cancer Immuno-Biotherapy (GETICA)
Oct 18, 2016·The American Journal of Pathology·Patrizio CaturegliIsabella Lupi
Jan 7, 2017·Oncotarget·Bo WangGuorui Ma
Jan 21, 2017·Nature Reviews. Endocrinology·David J ByunMonica Girotra
Sep 1, 2017·Melanoma Research·Aikaterini TsiogkaPeter Koelblinger
Sep 5, 2017·Diabetes Research and Clinical Practice·Toshie IijimaYoshimasa Aso
Sep 7, 2017·PloS One·Hector M GranadosAnthony T Vella
Jun 6, 2018·Nature Medicine·Nikolaos ZacharakisSteven A Feldman
Jun 26, 2018·Diabetes·Angeliki M StamatouliKevan C Herold
Jul 17, 2018·Pituitary·Hironori BandoYutaka Takahashi
Jul 5, 2016·Diabetology International·Hiroshi IkegamiShinsuke Noso
Citations
Jun 12, 2020·AACE Clinical Case Reports·Sara BedroseSonali N Thosani
Aug 26, 2020·Chinese Medical Journal·Rui ZhangLi-Nong Ji
Jul 17, 2020·Endocrine Journal·Erika AikawaAtsushi Kawakami
Nov 18, 2020·Cancer Immunology, Immunotherapy : CII·Zhe ZhaoDan Zhang
Oct 23, 2020·Diabetology International·Akihisa Imagawa, Megumi Tachibana
Mar 19, 2021·Frontiers in Oncology·Ya LiuXubao Liu
Mar 25, 2021·Pituitary·Pedro IglesiasJuan José Díez
Jan 5, 2021·Expert Opinion on Biological Therapy·Maria V DeligiorgiDimitrios T Trafalis
Jul 23, 2021·BMJ Case Reports·Koichi HataYukio Nagasaka
Nov 12, 2020·Case Reports in Oncology·Shoko MarshallHiroshi Sakura